UNSPSC 51312704: Clemastine fumarate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H26ClNO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19259EGQ3D, chemically known as pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (r-(r*,r*))- but more generally known as clemastine fumarate, which bears US NIH Compound Identifier 26987. European Medicines Agency schedules Clemastine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01335MIG.

UNSPSC 51312704 Clemastine fumarate is a Commodity code nominally addressing a single antihistamine product, but recent state and local solicitations tagged under this code show a mismatch with the abstract scope. The three recent opportunities posted under this UNSPSC include procurement of naloxone and drug deactivation systems, a pharmacy benefit program RFI focused on direct-to-manufacturer prescription channels, and a multistate cooperative pharmaceutical purchasing agreement covering generic multi-source drugs and over-the-counter products. None of these solicitations appears to target clemastine fumarate specifically, suggesting the code may be used inconsistently or as a default pharmaceutical placeholder within state and local procurement systems rather than as a precise commodity identifier.

Activity under this code spans state health agencies, county public health departments, and multistate cooperative purchasing vehicles. Seminole County, Florida issued an IFB on June 30, 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (note: date inconsistency in source), seeking 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the county community health building. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, reflecting state interest in alternative pharmacy supply chain models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026 with a response deadline of March 26, 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. The latter procurement weights price competitiveness at seventy-five percent and requires vendors to maintain cGMP and Drug Supply Chain Security Act compliance. Given the disconnect between the code name and actual solicitation scope, this code shows limited relevant recent activity for clemastine fumarate procurement specifically.